US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Hodgkin Disease

abstract

  • Response-adapted therapy based on interim PET imaging after two cycles of ABVD seems promising with a 2-year PFS of 64% for PET2-positive patients, which is much higher than the expected 2-year PFS of 15% to 30%.

publication date

  • June 10, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4966513

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.63.1119

PubMed ID

  • 27069074

Additional Document Info

start page

  • 2020

end page

  • 7

volume

  • 34

number

  • 17